Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $271.35 million
- Book Value:
- Revenue TTM:
- $138.59 million
- Operating Margin TTM:
- Gross Profit TTM:
- $20.46 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Codexis Inc had its IPO on 2010-04-22 under the ticker symbol CDXS.
The company operates in the Healthcare sector and Biotechnology industry. Codexis Inc has a staff strength of 248 employees.
Shares of Codexis Inc opened at $4.22 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $3.86 - $4.22, and closed at $3.89.
This is a -5.58% slip from the previous day's closing price.
A total volume of 788,600 shares were traded at the close of the day’s session.
In the last one week, shares of Codexis Inc have slipped by -10.57%.
Codexis Inc's Key Ratios
Codexis Inc has a market cap of $271.35 million, indicating a price to book ratio of 2.3781 and a price to sales ratio of 2.7321.
In the last 12-months Codexis Inc’s revenue was $138.59 million with a gross profit of $20.46 million and an EBITDA of $-26294000. The EBITDA ratio measures Codexis Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Codexis Inc’s operating margin was -22.88% while its return on assets stood at -7.98% with a return of equity of -21.73%.
In Q4, Codexis Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 24%.
Codexis Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.47 per share while it has a forward price to earnings multiple of 138.8889 and a PEG multiple of -1.16. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Codexis Inc’s profitability.
Codexis Inc stock is trading at a EV to sales ratio of 2.281 and a EV to EBITDA ratio of -13.3874. Its price to sales ratio in the trailing 12-months stood at 2.7321.
Codexis Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $41.04 million
- Total Liabilities
- $49.07 million
- Operating Cash Flow
- Capital Expenditure
- $9.24 million
- Dividend Payout Ratio
Codexis Inc ended 2023 with $41.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $41.04 million while shareholder equity stood at $144.80 million.
Codexis Inc ended 2023 with $0 in deferred long-term liabilities, $49.07 million in other current liabilities, 6000.00 in common stock, $-421290000.00 in retained earnings and $3.24 million in goodwill. Its cash balance stood at $113.98 million and cash and short-term investments were $113.98 million. The company’s total short-term debt was $5,360,000 while long-term debt stood at $0.
Codexis Inc’s total current assets stands at $162.89 million while long-term investments were $20.51 million and short-term investments were $0. Its net receivables were $34.02 million compared to accounts payable of $3.25 million and inventory worth $2.03 million.
In 2023, Codexis Inc's operating cash flow was $0 while its capital expenditure stood at $9.24 million.
Comparatively, Codexis Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Codexis Inc stock is currently trading at $3.89 per share. It touched a 52-week high of $22.22 and a 52-week low of $22.22. Analysts tracking the stock have a 12-month average target price of $14.25.
Its 50-day moving average was $5.52 and 200-day moving average was $6.77 The short ratio stood at 8.52 indicating a short percent outstanding of 0%.
Around 312.1% of the company’s stock are held by insiders while 9395.7% are held by institutions.
Frequently Asked Questions About Codexis Inc
Similar Industry Stocks (Biotechnology)
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company’s platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.